REQUEST A DEMO
Total
USD $0.00
Search more companies

Pt Organon Pharma Indonesia Tbk (Indonesia)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Pt Organon Pharma Indonesia Tbk Profile Updated: September 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

PT MSD Sharp Dohme Pharma Tbk is a biopharmaceutical company that focuses on vaccines, infectious diseases, cardio-metabolic disorders, biosimilars, women's health, diabetes, dermatology, and critical care. It has developed a 4-valent human papillomavirus (HPV) vaccine and has signed a technology transfer partnership with Bio Farma to locally manufacture the vaccine in Indonesia. PT MSD Sharp Dohme Pharma Tbk aims to reduce the number of cervical cancer cases in Indonesia and support the global strategy of the World Health Organization to accelerate the elimination of cervical cancer.

Headquarters
Wisma Bni 46, 27Th Floor, Suite 27.01 Jl. Jendral Sudirman Kav. 1
Jakarta; Jakarta; Postal Code: 10220

Contact Details: Purchase the Pt Organon Pharma Indonesia Tbk report to view the information.

Website: http://www.msd-indonesia.com

Basic Information
Total Employees:
Purchase the Pt Organon Pharma Indonesia Tbk report to view the information.
Outstanding Shares:
Purchase the Pt Organon Pharma Indonesia Tbk report to view the information.
Financial Auditors:
Purchase the Pt Organon Pharma Indonesia Tbk report to view the information.
Incorporation Date:
1972
Key Executives
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
98.79%
Purchase this report to view the information.
1.21%
Company Performance
Financial values in the chart are available after Pt Organon Pharma Indonesia Tbk report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency IDR. Absolute financial data is included in the purchased report.
Net sales revenue
9.47%
Total operating revenue
9.68%
Operating profit (EBIT)
-10.66%
EBITDA
-10.35%
Net Profit (Loss) for the Period
-17.16%
Total assets
8.36%
Total equity
1.28%
Operating Profit Margin (ROS)
-2.67%
Net Profit Margin
-2.66%
Return on Equity (ROE)
-2.61%
Debt to Equity Ratio
-0.32%
Quick Ratio
-0.33%
Cash Ratio
-0.35%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?